These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 10963197)
1. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Kahan BD Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197 [TBL] [Abstract][Full Text] [Related]
2. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. MacDonald AS; Transplantation; 2001 Jan; 71(2):271-80. PubMed ID: 11213073 [TBL] [Abstract][Full Text] [Related]
3. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768 [TBL] [Abstract][Full Text] [Related]
4. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP; Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789 [TBL] [Abstract][Full Text] [Related]
5. Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine. Machado PG; Felipe CR; Park SI; Garcia R; Moreira S; Casarini D; Franco M; Alfieri F; Tedesco-Silva H; Medina-Pestana JO Braz J Med Biol Res; 2004 Sep; 37(9):1303-12. PubMed ID: 15334195 [TBL] [Abstract][Full Text] [Related]
6. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489 [TBL] [Abstract][Full Text] [Related]
8. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738 [TBL] [Abstract][Full Text] [Related]
9. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection. Tsai MK; Chueh SC; Hu RH; Lee PH J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737 [TBL] [Abstract][Full Text] [Related]
10. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559 [TBL] [Abstract][Full Text] [Related]
11. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results. Machado PG; Garcia C; Felipe CR; Garcia R; Franco M; Delcelo R; Silva HT; Medina JO Transplant Proc; 2001; 33(1-2):1074-5. PubMed ID: 11267196 [No Abstract] [Full Text] [Related]
12. A randomized trial comparing cyclosporine and steroids with cyclosporine, azathioprine, and steroids in cadaveric renal transplantation. Amenábar JJ; Gómez-Ullate P; García-López FJ; Aurrecoechea B; García-Erauzkin G; Lampreabe I Transplantation; 1998 Mar; 65(5):653-61. PubMed ID: 9521199 [TBL] [Abstract][Full Text] [Related]
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months. Aichberger C; Eberl T; Riedmann B; Pernthaler H; Ofner D; Königsrainer A; Margreiter R Clin Transplant; 1996 Apr; 10(2):209-12. PubMed ID: 8664521 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Ettenger RB; Grimm EM Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941 [TBL] [Abstract][Full Text] [Related]
16. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Keogh A; Richardson M; Ruygrok P; Spratt P; Galbraith A; O'Driscoll G; Macdonald P; Esmore D; Muller D; Faddy S Circulation; 2004 Oct; 110(17):2694-700. PubMed ID: 15262845 [TBL] [Abstract][Full Text] [Related]
17. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Kahan BD; Kaplan B; Lorber MI; Winkler M; Cambon N; Boger RS Transplantation; 2001 May; 71(10):1400-6. PubMed ID: 11391226 [TBL] [Abstract][Full Text] [Related]
18. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe). Ponticelli C; Tarantino A; Segoloni GP; Cambi V; Rizzo G; Altieri P; Mastrangelo F; Castagneto M; Salvadori M; Valente U; Cossu M; Federico S; Pisani F; Montagnino G; Messina M; Arisi L; Carmellini M; Piredda G; Corbetta G J Am Soc Nephrol; 1997 Apr; 8(4):638-46. PubMed ID: 10495794 [TBL] [Abstract][Full Text] [Related]
19. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P; N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570 [TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]